Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Liquidia Corp

LQDA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$74.44

▲ +3.25%

Market Cap $6.66B · Vol 763.37K

Key Metrics

P/E Ratio

53.71

FWD: 15.80

Market Cap

$6.66B

Mid Cap

Div Yield

N/A

EPS Growth

+475.72%

YoY

RSI (14)

35.25

Momentum

Beta

0.52

vs Market

52W High

$93.58

20.45% below

52W Low

$21.15

251.96% above

Volume

763.37K

Avg 498.24K

P/B

67.21

Price-to-book

ROE

-112.97%

Return on equity

Free Float

87.21%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Liquidia Corp (LQDA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LQDA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-17.49%

-2.68%

+25.53%

+94.87%

YTD

+115.83%

+185.32%

+968.01%

+2,698.50%

Financials & Valuation

TTM · Annual

Total Revenue	$158.32M
Net Income	$-68,924,000.00
Revenue Growth (YoY)	+1,842.73%
Gross Margin	91.64%
Operating Margin	-32.45%
Net Profit Margin	-43.53%
ROE	-112.97%
ROA · ROIC	-24.69% · N/A

P/E Ratio	53.71
Forward P/E (FY1)	15.80
PEG Ratio	N/A
P/S	18.75
P/B	67.21
P/FCF	N/A
EPS Growth	+475.72%
Outstanding Shares	89.51M

Technical Indicators

50-Day SMA	$78.16
200-Day SMA	$48.02
RSI (14)	35.25
Beta	0.52
52-Week High	$93.58
52-Week Low	$21.15

Volume Today	763.37K
Avg Daily Volume (30D)	498.24K
Relative Volume	1.53x
Volatility (10D)	77.26
Volatility (30D)	70.66
Free Float	87.21%

Analyst Consensus

BUY

Current Price $74.44

Mean Target $105.54

52W Low$21.15 52W High$93.58

Current

Target

$21.15 $93.58

Current Analyst target

+41.78% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GFD7

ISINUS53635D2027

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.